The pathogenic role of dysregulated IL-6 in rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, giant cell arteritis, and cytokine release syndrome has been supported by the efficacy of IL-6-targeted therapies [24]. This evidence concerns the gene IL6 and arteritis.